TORONTO, ONTARIO--(Marketwired - Jan. 23, 2014) - Trimel Pharmaceuticals Corporation (TSX:TRL) is pleased to announce the appointment of Dr. Nathan Bryson to the position of Vice President, Scientific Affairs. Dr. Bryson will replace Mr. Wayne Kreppner who has elected to pursue other opportunities. Dr. Bryson will be responsible for all areas of the Company's research and development activities as well as leading the clinical, regulatory affairs, and manufacturing functions.
Dr. Bryson joins Trimel from Cynapsus Therapeutics where he served as Chief Scientific Officer. He brings more than 20 years of experience in pharmaceutical development, having held scientific and executive management level positions at several pharmaceutical companies including Flamel Technologies SA, Bionisis SA, and Matregen Corporation. Dr. Bryson holds a BSc in Chemistry from Auburn University and a PhD in Radiopharmaceutical Chemistry from the Massachusetts Institute of Technology ("MIT"). He performed post-doctoral research under two well-esteemed chemists, the late Dr. J. Osborn at the University Louis Pasteur (Strasbourg, France) and Dr. D. Seyfeth at MIT.
"We are thrilled to welcome Dr. Bryson to the Company and to the executive team," stated Tom Rossi, President and Chief Executive Officer. "With his impressive academic credentials that complement his extensive experience in the pharmaceutical industry, we believe he is ideally suited to oversee our ongoing drug development opportunities as we work to further the growth of Trimel. I would also like to thank Mr. Kreppner for his many contributions over the last five years and wish him good luck with his future endeavours."
Trimel's most advanced product candidate, CompleoTRT™, is a bioadhesive intranasal gel formulation of testosterone. CompleoTRT™ is designed with a view to providing hypogonadal patients with superior safety and enhanced convenience over currently available treatment options.
Trimel is a specialty pharmaceutical company actively developing medications for male hypogonadism, female sexual dysfunction and various respiratory disorders. An NDA for CompleoTRT™, a product utilizing Trimel's licensed bioadhesive intranasal gel technology, has been accepted for review by the FDA for regulatory approval in the United States. For more information, please visit www.trimelpharmaceuticals.com.